Norstella’s Post

In our blog post, Daniel Chancellor suggests that rather than becoming more risk-averse, drug developers should seek to shift attrition to the earliest stages of development. This allows for prioritization of the best assets with the most significant patient impact. Click to read about why clinical development success rates are falling on the Norstella blog: https://ow.ly/7eIp50RIMsC. #ClinicalDevelopment #DrugDevelopment #Biopharma #BiopharmaceuticalCompanies #BiopharmaTrends

Citeline's influential clinical development success rate analyses have been foundational for supporting investment decisions in biopharma R&D. Our landmark paper in 2014 established the commonly cited 10% benchmark. However, this has steadily fallen over the last decade. This drop is both a concern and inevitable as competition intensifies and the barriers to market entry become higher. Click to read about why clinical development success rates are falling on the Norstella blog: https://ow.ly/E12a50RIPZF. #ClinicalDevelopment #DrugDevelopment #Biopharma #BiopharmaceuticalCompanies #BiopharmaTrends

Citeline’s influential clinical development success rate analyses have been foundational for supporting investment decisions in biopharma R&D. Our landmark paper in 2014 established the commonly cited 10% benchmark. However, this has steadily fallen over the last decade. This drop is both a concern and inevitable as competition intensifies and the barriers to market entry become higher. Click to read about why clinical development success rates are falling on the Norstella blog: https://ow.ly/4fh250RIMpu. #ClinicalDevelopment #DrugDevelopment #Biopharma #BiopharmaceuticalCompanies #BiopharmaTrends

AI drug development represents a seismic shift in healthcare innovation. By leveraging advanced algorithms and vast datasets, AI accelerates the drug discovery process, leading to faster and more efficient development of novel therapeutics. This transformative technology enables researchers to analyze complex biological systems, identify promising drug candidates, and predict their efficacy and safety with unprecedented accuracy. The future is bright with possibility. #AI #DrugDevelopment #Healthcare #Innovation #Data #DrugDiscovery

New Publication Alert: Advancing Drug-Drug Interaction Prediction with a Simplified Similarity-Based Approach I’m excited to share our latest research article, the result of a collaborative journey with my esteemed colleagues Adir Solomon, Eyal Mazuz, Lior Rokach, and Bracha Shapira. This work extends my previous research, marking a significant advancement in the prediction of drug interactions at the earliest stages of drug development. Our approach demonstrates the power of simplicity in overcoming complex challenges in scientific research. This publication is a testament to perseverance. Despite facing numerous rejections, we remained steadfast in our pursuit. Each challenge was a stepping stone, eventually leading us to find the perfect platform for our work. Our method not only streamlines the prediction process but also opens new avenues for safer and more efficient drug development. It represents a meaningful advancement in pharmaceutical research, providing a robust tool for early detection of potential drug interactions. I am eager to share our findings with the scientific community and beyond. I welcome your thoughts and feedback. #DrugDevelopment #ResearchCollaboration #NeverGiveUp #InnovationInScience

The integration of AI in drug development (as exemplified by INS018_055's journey to phase 2 clinical trials) not only showcases the potential for accelerating innovation but also demonstrates the vital role of collaboration between technology and pharmaceutical expertise. This breakthrough highlights a potentially pivotal moment in healthcare that could bring in a future where AI-driven solutions could mitigate the longstanding challenges of time and cost in bringing life-saving medications to market. #AI #DrugDevelopment #ClinicalTrials #Healthcare

“Multiple factors underlie low R&D productivity: consistently low success rates (about 13% of assets that enter the Phase 1 trial stage go on to launch) development costs remain high (as much as 60 to 70% of total costs) and development cycles are long (taking an average of 12 years to develop a novel medicine)” According to this article by Gaurav Agrawal for McKinsey & Company, despite experiencing a period of strong innovation in the #biopharmaceutical sector, with 4,300 clinical trials launched in 2022 alone, R&D productivity remains stubbornly low. What are the main factors playing a role in this situation? Could virtual humans in trials have an impact on it? Read the entire article to get an answer to the first question and contact us for a demonstration of our #digitaltwin at [email protected] to get an answer to the second! 👉https://lnkd.in/gb-EMR7R #Healthtech #medtech #clinicaltrials

Who is overseeing your CRA/site monitors? Do you need a SWAT team of monitors to perform SDV/source data verification? We have an experienced and nimble team ready to go. CRAs are the eyes-and-ears at clinical trial sites and play an important role for monitoring your clinical trial. How confident are you in their activity? Contact us at [email protected] for a free consultation. Amy Longcore and her team will help your data achieve a #SafeLanding. At Blue Parachute, we've got your back! #BlueParachute #CRA #Monitoring #ClinicalMonitoring #SDV #DataQuality #Biotechnology #BioPharmaceutical #ClinicalDevelopment #ClinicalTrials #ClinicalOperations #Pharmaceutical #ClinicalResearch #Protocol #DrugDevelopment #ClinicalMonitoring #ClinicalDataManagement #RegulatoryAffairs #Oncology #Diabetes #Cardiovascular #ClinicalTrialEfficiency

Age Related Macular Degeneration Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Amgen, Roche, Adverum Biotechnologies, AsclepiX #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

🚀 Exciting Insights in Drug Development 🌐 📊 We surveyed 150 drug developers around the globe to assess drug development trends and opportunities. Here’s what we found: ✅ Drug developers face challenges in patient recruitment and increasing trial complexity. ✅Decentralized trials are becoming standard. ✅Outsourcing favors functional service provider (FSP) and hybrid models. ✅Clinical trial timelines are improving for larger sponsors and Asian companies. ✅Patient diversity is a priority, especially for larger sponsors. ✅Oncology trials are growing in complexity. ✅AI has potential to expedite clinical trials but faces adoption challenges. Click on the link below to read the full article. PPD Thermo Fisher Scientific #PPD #pharma #biotech #drugdevelopment #lifesciences #PharmaTrends #InnovationInHealthcare #